AnGes, Inc. has provided update regarding joint development between Osaka University and AnGes for DNA vaccine targeting novel coronavirus announced on March 5, production of the plasmid DNA vaccine has been completed for preclinical studies. The animal testing will be launched shortly. The preclinical studies will be conducted to evaluate antibody productivity, efficacy and safety by administration to the mice, rats and monkeys. This process enables to proceed to clinical trials for healthy volunteers. Joint development of DNA vaccine against novel coronavirus between AnGes and Osaka University (Department of Clinical Gene Therapy; Department of Health Development and Medicine) based on the previous achievement of plasmid DNA product. The manufacturing process can be established in a shorter period of time with the manufacture of DNA vaccines, compared with the vaccine with using inactivated viruses (attenuated vaccines) or the vaccine with using genetically modified virus protein. The manufacturing operations will be undertaken by Takara Bio Inc. that possesses manufacturing technology and facilities of plasmid DNA. Daicel is developing an intradermal gene transfer method, using this new administration device, and promote research with Osaka University (Impulse Science for Medicine; Department of Health Development and Medicine), aiming at its clinical application. Use of this new administration device is expected to increase the efficiency of intradermal genetic expression and antibody production capability, enabling the development of more efficient DNA vaccines.